AstraZeneca's Tezspire Secures FDA Nod for Treating Nasal Polyps

AstraZenecas Tezspire has received FDA approval for treating chronic rhinosinusitis with nasal polyps, marking a significant advancement in managing inflammation for millions worldwide.

• The Food and Drug Administration approved Tezspire (tezepelumab) as an add-on maintenance treatment for adults and patients aged 12 years and older with inadequately controlled nasal polyp conditions.
• Chronic rhinosinusitis with nasal polyps affects approximately 320 million people globally, highlighting the urgent need for effective treatments beyond traditional corticosteroid therapies.
• Tezspire is the first biologic targeting thymic stromal lymphopoietin, offering a new approach to addressing inflammation related to nasal polyp and sinusitis conditions, which can also be exacerbated by allergy.